Alphamab Oncology (HKG:9966)

Market Cap	9.12B +18.1%
Revenue (ttm)	630.11M -11.5%
Net Income	-126.79M
EPS	-0.13
Shares Out	968.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,655,000
Open	9.68
Previous Close	9.85
Day's Range	9.37 - 9.79
52-Week Range	6.01 - 15.75
Beta	0.58
Analysts	Buy
Price Target	11.95 (+26.86%)
Earnings Date	Mar 25, 2026

About Alphamab Oncology

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People’s Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 498
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9966

Financial Performance

Financial numbers in CNY